-
US warns of rapid escalation in Mideast war
-
PSG president Nasser al-Khelaifi under investigation in France for conflict of interest
-
Iran 'put hearts on the court' to win Asian Games basketball bronze
-
China swim sensation, 13, sets Games record after Japan win early
-
School girl Yu helps China dominate in Asian Games swimming openers
-
Drones hit Moscow as Russians go to the polls
-
Myanmar win first Asian Games teqball gold as Spain great Puyol watches
-
New England boss Fleming says 'wrong' to ask Stokes to end retirement
-
China's 13-year-old Yu scorches to first major gold at Asian Games
-
Germans vote in elections threatening fresh blow to Merz
-
Russians vote on last day of parliamentary elections
-
US fears rapid escalation in Mideast after Houthis attack Riyadh
-
Hong Kong pays final respects to former city leader Tung
-
Japan triathlete Hojo wins first gold of Asian Games
-
Typhoon put people off Asian Games opening ceremony, official says
-
IOC president impressed by 'beautiful' Asian Games wooden huts
-
China's 13-year-old Yu cruises as Asian Games swimming begins
-
First Asian Games gold goes to Japan as China's 13-year-old Yu lights up pool
-
AI 'warning shots' focus Beijing on national security risks
-
Data centre command hub keeps AI up and running
-
Philippine tribe in limbo over US-led tech hub
-
Pope Leo in France: the issues on the table
-
Leo XIV, first US pope transcends his restrained style
-
Packing for a pope: behind the scenes on foreign trips
-
Singer Ed Sheeran says Gaza situation 'unjustifiable' following controversy
-
Republicans find transgender issues a powerful political weapon in midterm campaigning
-
In 'Tenzing', a Sherpa mountaineer gets his due
-
German state elections threaten new shock waves for Merz
-
Ed Sheeran set to return to stage after Palestinian controversy
-
Chile's Bachelet quits race to be next UN chief
-
Toulouse edge Vannes, Lyon beat Pau to take Top 14 summit
-
Raphinha treble fires perfect Barca to win at Sevilla
-
Germans arrested for Louvre stunt in Mona Lisa hall
-
Thiam makes winning heptathlon return at Decastar meet
-
Saudi-led coalition says Houthis fired ballistic missile at Riyadh
-
Czechs beat USA to qualify for Davis Cup finals
-
France's debt climbs to highest since 1978: ministry
-
Dortmund sink Stuttgart to climb to Bundesliga summit
-
McIlroy two shots off the lead at Wentworth after eagle on 18
-
Trump says will not tolerate attempts to slow AI growth
-
Martinez brace saves Inter in Serie A top-two clash with Roma
-
'It has to stop': runners protest women's murders in S.Africa district
-
Rosenior abused but guides Paris FC past old club Strasbourg
-
Fire erupts near Riyadh airport as Houthis claim strikes
-
Seven-try Lyon beat Pau, climb to Top 14 summit
-
Cuba works to restore power after another blackout
-
Brighton defeat a 'big lesson' against complacency for Arsenal, says Arteta
-
England thrash Sri Lanka again to return to top of T20 rankings
-
Thousands protest inaction over climate crisis in Switzerland
-
Arsenal thrashed by Brighton, sorry Spurs lose again
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Salvador--PC